Agenus shifts to BOT+BAL in neoadjuvant MSS colon cancer; $85M raise extends runway to 2031. Click here to read this latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results